ERBB2 and gastric cancer: Recent developments in regard to antibody–drug conjugates targeting ERBB2, such as trastuzumab deruxtecan (T-DXd), have demonstrated promising efficacy in regard to ERBB2-positive gastric cancer [25], and their activity in the context of specific ERBB2 mutations warrants further investigation.